Molecular imaging as a guide for the treatment of central nervous system disorders

Dialogues in Clinical Neuroscience

Volumn 15, Issue 3, 2013, Pages 315-328

  Kim, Euitae ^a   Howes, Oliver D ^b,c   Kapur, Shitij ^c  

^a Seoul National University Bundang Hospital   (South Korea)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Dementia; Depression; Molecular imaging; Parkinson's disease; Positron emission tomography; Schizophrenia; Single photon emission computed tomography

Indexed keywords

4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; ALPHA SYNUCLEIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CATECHOL METHYLTRANSFERASE INHIBITOR; CHLORPROMAZINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; FLUTEMETAMOL F 18; GLYCINE TRANSPORTER; IMIPRAMINE; IOFLUPANE I 123; KETAMINE; MONOAMINE OXIDASE B INHIBITOR; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; NEUROLEPTIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; NORADRENALIN; NORADRENALIN TRANSPORTER; PITTSBURGH COMPOUND B; POMAGLUMETAD METHIONIL; RACLOPRIDE C 11; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; VESICULAR MONOAMINE TRANSPORTER 2;

ALZHEIMER DISEASE; ARTICLE; BIPOLAR DISORDER; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; CAUDATE NUCLEUS; CENTRAL NERVOUS SYSTEM DISEASE; COGNITION; COGNITIVE DEFECT; CORTICOBASAL DEGENERATION; DEMENTIA; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; EARLY DIAGNOSIS; HUMAN; MAJOR DEPRESSION; META ANALYSIS (TOPIC); MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGICAL PROCESS; POSITIVE SYNDROME; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PREFRONTAL CORTEX; PROGRESSIVE SUPRANUCLEAR PALSY; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VERBAL MEMORY; VISUAL MEMORY;

DEPRESSION; MOLECULAR IMAGING; PARKINSON'S DISEASE, DEMENTIA; POSITRON EMISSION TOMOGRAPHY; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY;

ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; MOLECULAR IMAGING; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84888074554     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (176)

1. Weissleder R, Mahmood U. Molecular imaging. Radiology. 2001; 219:316-333.
2. Hedreen JC. Lost caps in histological counting methods. Anat Rec. 1998; 250:366-372.
3. Jablensky A. Epidemiology of schizophrenia:the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci. 2000; 250:274-285.
4. Howes OD, Egerton A, Allan V, Mcguire P, Stokes P, Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia:insights from PET and SPECT imaging. Curr Pharm Des. 2009; 15:2550-2559.
5. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 1975; 188:1217-1219.
6. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976; 192:481-483.
7. Cross AJ, Crow TJ, Owen F. 3H-Flupenthixol binding in post-mortem brains of schizophrenics: evidence for a selective increase in dopamine D2 receptors. Psychopharmacology (Berl). 1981; 74:122-124.
8. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull. 2009; 35:549-562.
9. Howes OD, Kambeitz J, Kim E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012; 69:776-786.
10. Reith J, Benkelfat C, Sherwin A, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A. 1994; 91:11651-11654.
11. Laakso A, Vilkman H, Alakare B, et al. Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am J Psychiatry. 2000; 157:269-271.
12. Wong DF, Wagner HN, Jr, Tune LE, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science. 1986; 234:1558-1563.
13. Farde L, Wiesel FA, Stone-Elander S, et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry. 1990; 47:213-219.
14. Laruelle M, Abi-Dargham A, van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A. 1996; 93:9235-9240.
15. Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations:evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A. 1997; 94:2569-2574.
16. Stokes PR, Shotbolt P, Mehta MA, et al. Nature or nurture? Determining the heritability of human striatal dopamine function:an [18F]-DOPA PET study. Neuropsychopharmacology. 2013; 38:485-491.
17. Bose SK, Turkheimer FE, Howes OD, et al. Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. Schizophr Res. 2008; 106:148-155.
18. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Grasby PM, Mcguire PK. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry Suppl. 2007;51:s13-18.
19. Shotbolt P, Stokes PR, Owens SF, et al. Striatal dopamine synthesis capacity in twins discordant for schizophrenia. Psychol Med. 2011; 41:2331-2338.
20. Howes OD, Shotbolt P, Bloomfield M, et al. Dopaminergic function in the psychosis spectrum: an [18F]-DOPA imaging study in healthy individuals with auditory hallucinations. Schizophr Bull. 2012.
21. Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009; 66:13-20.
22. Howes O, Bose S, Turkheimer F, et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis:a PET study. Mol Psychiatry. 2011; 16:885-886.
23. Howes OD, Bose SK, Turkheimer F, et al. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry. 2011; 168:1311-1317.
24. Egerton A, Chaddock CA, Winton-Brown TT, et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis:findings in a second cohort. Biol Psychiatry. 2013; 74:106-112.
25. Ingvar DH, Franzen G. Distribution of cerebral activity in chronic schizophrenia. Lancet. 1974; 2:1484-1486.
26. Ingvar DH, Franzen G. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand. 1974; 50:425-462.
27. Hill K, Mann L, Laws KR, Stephenson CM, Nimmo-Smith I, Mckenna PJ. Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr Scand. 2004; 110:243-256.
28. Molina V, Sanz J, Reig S, et al. Hypofrontality in men with first-episode psychosis. Br J Psychiatry. 2005; 186:203-208.
29. Bose SK, Mackinnon T, Mehta MA, et al. The effect of ageing on grey and white matter reductions in schizophrenia. Schizophr Res. 2009; 112:7-13.
30. Zakzanis KK, Heinrichs RW. Schizophrenia and the frontal brain: a quantitative review. J Int Neuropsychol Soc. 1999; 5:556-566.
31. Bannon MJ, Roth RH. Pharmacology of mesocortical dopamine neurons. Pharmacol Rev. 1983; 35:53-68.
32. Andreasen NC. Brain imaging: applications in psychiatry. Science. 1988; 239:1381-1388.
33. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia:ca review and reconceptualization. Am J Psychiatry. 1991; 148:1474-1486.
34. Howes OD, Fusar-Poli P, Bloomfield M, Selvaraj S, Mcguire P. From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairments. Curr Pharm Des. 2012; 18:459-465.
35. Vernaleken I, Kumakura Y, Cumming P, et al. Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. Neuroimage. 2006; 30:1332-1339.
36. Mcgowan S, Lawrence AD, Sales T, Quested D, Grasby P. Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry. 2004; 61:134-142.
37. Demjaha A, Murray RM, Mcguire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012; 169:1203-1210.
38. Talbot PS, Laruelle M. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol. 2002; 12:503-511.
39. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999; 156:286-293.
40. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000; 157:514-520.
41. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992; 49:538-544.
42. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 1989; 25:390-392.
43. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996; 153:466-476.
44. Mamo D, Kapur S, Shammi CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004; 161:818-825.
45. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia:a PET investigation. Am J Psychiatry. 1998; 155:921-928.
46. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry. 2001; 158:360-369.
47. Sesack SR, Carr DB, Omelchenko N, Pinto A. Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. Ann N Y Acad Sci. 2003; 1003:36-52.
48. Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia--therapeutic implications. Biol Psychiatry. 1999; 46:1388-1395.
49. Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci. 2003; 1003:138-158.
50. Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin Ther. 2005;27(SUPPL A):S16-24.
51. Grunze HC, Rainnie DG, Hasselmo ME, et al. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci. 1996; 16:2034-2043.
52. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine:a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997; 17:2921-2927.
53. Adams BW, Moghaddam B. Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol Psychiatry. 2001; 50:750-757.
54. Rowland LM, Bustillo JR, Mullins PG, et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry. 2005; 162:394-396.
55. Lopez-Gil X, Babot Z, Amargos-Bosch M, Sunol C, Artigas F, Adell A. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology. 2007; 32:2087-2097.
56. Curras MC, Pallotta BS. Single-channel evidence for glycine and NMDA requirement in NMDA receptor activation. Brain Res. 1996; 740:27-40.
57. Choi DW, Koh JY, Peters S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J Neurosci. 1988; 8:185-196.
58. Lane HY, Liu YC, Huang CL, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry. 2008; 63:9-12.
59. Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol. 2010; 13:451-460.
60. Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol. 2010; 77:317-326.
61. Battaglia G, Monn JA, Schoepp DD. In vivo inhibition of veratridineevoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci Lett. 1997; 229:161-164.
62. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007; 13:1102-1107.
63. Lilly announces pomaglumetad methionil did not meet primary endpoint of clinical study. Available at: http://newsroom.lilly.com/ releasedetail.cfm?releaseid=690836. Company ELa. Accessed May 21, 2013.
64. Lilly stops phase III development of pomaglumetad methionil for the treatment of schizophrenia based on efficacy results. Available at: http://newsroom.lilly.com/releasedetail.cfm?releaseid=703018. Company ELa. Accessed May 21, 2013.
65. Homayoun H, Stefani MR, Adams BW, Tamagan GD, Moghaddam B. Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology. 2004; 29:1259-1269.
66. Liu F, Grauer S, Kelley C, et al. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]:a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther. 2008; 327:827-839.
67. Homayoun H, Moghaddam B. Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs. Proc Natl Acad Sci U S A. 2008; 105:18041-18046.
68. Wang JQ, Zhang Z, Kuruppu D, Brownell AL. Radiosynthesis of PET radiotracer as a prodrug for imaging group II metabotropic glutamate receptors in vivo. Bioorg Med Chem Lett. 2012; 22:1958-1962.
69. Delorenzo C, Kumar JS, Mann JJ, Parsey RV. In vivo variation in metabotropic glutamate receptor subtype 5 binding using positron emission tomography and [11C]ABP688. J Cereb Blood Flow Metab. 2011; 31:2169-2180.
70. Wong DF, Ostrowitzki S, Zhou Y, et al. Characterization of [(11)C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans. Neuroimage. 2011; 75:282-290.
71. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry. 2002; 7:317-321.
72. Gefvert O, Bergstrom M, Langstrom B, Lundberg T, Lindstrom L, Yates R. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl). 1998; 135:119-126.
73. Kim E, Howes OD, Kim BH, et al. Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship. J Cereb Blood Flow Metab. 2012; 32:759-768.
74. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289:3095-3105.
75. Pincus HA, Pettit AR. The societal costs of chronic major depression. J Clin Psychiatry. 2001;62 (SUPPL 6):5-9.
76. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med. 1998; 4:1241-1243.
77. Albert PR, Benkelfat C, Descarries L. The neurobiology of depression--revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms. Philos Trans R Soc Lond B Biol Sci. 2012; 367:2378-2381.
78. Clasen PC, Wells TT, Knopik VS, Mcgeary JE, Beevers CG. 5-HTTLPR and BDNF Val66Met polymorphisms moderate effects of stress on rumination. Genes Brain Behav. 2011; 10:740-746.
79. Drevets WC, Thase ME, Moses-Kolko EL, et al. Serotonin-1A receptor imaging in recurrent depression:replication and literature review. Nucl Med Biol. 2007; 34:865-877.
80. Drevets WC, Frank E, Price JC, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry. 1999; 46:1375-1387.
81. Sargent PA, Kjaer KH, Bench CJ, et al. Brain serotonin 1A receptor binding measured by positron emission tomography with [11C]WAY-100635:effects of depression and antidepressant treatment. Arch Gen Psychiatry. 2000; 57:174-180.
82. Meltzer CC, Price JC, Mathis CA, et al. Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology. 2004; 29:2258-2265.
83. Parsey RV, Ogden RT, Miller JM, et al. Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations. Biol Psychiatry. 2010; 68:170-178.
84. Shrestha S, Hirvonen J, Hines CS, et al. Serotonin-1A receptors in major depression quantified using PET: controversies, confounds, and recommendations. Neuroimage. 2012; 59:3243-3251.
85. Parsey RV, Oquendo MA, Ogden RT, et al. Altered serotonin 1A binding in major depression:a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry. 2006; 59:106-113.
86. Murrough JW, Henry S, Hu J, et al. Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder. Psychopharmacology (Berl). 2011; 213:547-553.
87. Meyer JH, Houle S, Sagrati S, et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry. 2004; 61:1271-1279.
88. Cannon DM, Ichise M, Rollis D, et al. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry. 2007; 62:870-877.
89. Bhagwagar Z, Murthy N, Selvaraj S, et al. 5-HTT binding in recovered depressed patients and healthy volunteers: a positron emission tomography study with [11C]DASB. Am J Psychiatry. 2007; 164:1858-1865.
90. Reimold M, Batra A, Knobel A, et al. Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression:a [11C]DASB PET study. Mol Psychiatry. 2008;13:606-613, 557.
91. Selvaraj S, Murthy NV, Bhagwagar Z, et al. Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [11C]DASB. Psychopharmacology (Berl). 2011; 213:555-562.
92. Reimold M, Knobel A, Rapp MA, et al. Central serotonin transporter levels are associated with stress hormone response and anxiety. Psychopharmacology (Berl). 2011; 213:563-572.
93. Frokjaer VG, Vinberg M, Erritzoe D, et al. High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. Neuroimage. 2009; 46:360-366.
94. Miller JM, Hesselgrave N, Ogden RT, et al. Positron emission tomography quantification of serotonin transporter in suicide attempters with major depressive disorder. Biol Psychiatry. 2013; 74:287-295.
95. Meyer JH, Ginovart N, Boovariwala A, et al. Elevated monoamine oxidase a levels in the brain:an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006; 63:1209-1216.
96. Meyer JH, Wilson AA, Sagrati S, et al. Brain monoamine oxidase A binding in major depressive disorder:relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch Gen Psychiatry. 2009; 66:1304-1312.
97. Parsey RV, Oquendo MA, Zea-Ponce Y, et al. Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry. 2001; 50:313-322.
98. Allard P, Norlen M. Caudate nucleus dopamine D(2) receptors in depressed suicide victims. Neuropsychobiology. 2001; 44:70-73.
99. Savitz JB, Drevets WC. Neuroreceptor imaging in depression. Neurobiol Dis 2013;52:49-65.
100. Mark C, Bornatowicz B, Mitterhauser M, et al. Development and automation of a novel NET-PET tracer:[11C]Me@APPI. Nucl Med Biol. 2013;40:295-303
101. Ding YS, Lin KS, Logan J. PET imaging of norepinephrine transporters. Curr Pharm Des. 2006;12:3831-3845
102. Prabhakaran J, Majo VJ, Milak MS, et al. Synthesis and in vivo evaluation of [11C]MPTQ:a potential PET tracer for alpha2A-adrenergic receptors. Bioorg Med Chem Lett. 2010;20:3654-3657
103. Nord M, Finnema SJ, Halldin C, Farde L. Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. Int J Neuropsychopharmacol. 2013; 16:1577-1586.
104. Quednow BB, Treyer V, Hasler F, et al. Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography. Neuroimage. 2012; 59:3922-3932.
105. Selvaraj S, Turkheimer F, Rosso L, et al. Measuring endogenous changes in serotonergic neurotransmission in humans:a [11C]CUMI-101 PET challenge study. Mol Psychiatry. 2012; 17:1254-1260.
106. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004; 161:826-835.
107. Malagie I, Trillat AC, Jacquot C, Gardier AM. Effects of acute fluoxetine on extracellular serotonin levels in the raphe:an in vivo microdialysis study. Eur J Pharmacol. 1995; 286:213-217.
108. Gartside SE, Umbers V, Hajos M, Sharp T. Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo:effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol. 1995; 115:1064-1070.
109. Bel N, Artigas F. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei:an in vivo microdialysis study. Eur J Pharmacol. 1992; 229:101-103.
110. Romero L, Artigas F. Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors. J Neurochem. 1997; 68:2593-2603.
111. Hjorth S, Auerbach SB. 5-HT1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI). Behav Brain Res. 1996; 73:281-283.
112. Invernizzi R, Belli S, Samanin R. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res. 1992; 584:322-324.
113. Chaput Y, de Montigny C, Blier P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1986; 333:342-348.
114. Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008; 33:2080-2092.
115. Aan Het Rot M, Zarate CA, Jr, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012; 72:537-547.
116. Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neurosci. 2003; 26:81-104.
117. Wang J, Zuo CT, Jiang YP, et al. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. J Neurol. 2007; 254:185-190.
118. Broussolle E, Dentresangle C, Landais P, et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci. 1999; 166:141-151.
119. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Annals Neurol. 1997; 41:58-64.
120. Vingerhoets FJ, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol. 1994; 36:759-764.
121. Nurmi E, Ruottinen HM, Bergman J, et al. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord. 2001; 16:608-615.
122. Fearnley JM, Lees AJ. Ageing and Parkinson's disease:substantia nigra regional selectivity. Brain. 1991;114(PT 5):2283-2301.
123. Bruck A, Aalto S, Rauhala E, Bergman J, Marttila R, Rinne JO. A followup study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen. Mov Disord. 2009; 24:1009-1015.
124. Pavese N, Simpson BS, Metta V, Ramlackhansingh A, Chaudhuri KR, Brooks DJ. [(1)(8)F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [(1)(8)F]FDOPA and [(1)(1)C]DASB PET study in Parkinson's disease. Neuroimage. 2012; 59:1080-1084.
125. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ, study CWP. Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology. 2003; 60:601-605.
126. Politis M, Wu K, Loane C, et al. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis. 2010; 40:216-221.
127. Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain. 2010; 133:3434-3443.
128. Jokinen P, Bruck A, Aalto S, Forsback S, Parkkola R, Rinne JO. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord. 2009; 15:88-93.
129. Cropley VL, Fujita M, Bara-Jimenez W, et al. Pre-and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatry Res. 2008; 163:171-182.
130. Borghammer P, Chakravarty M, Jonsdottir KY, et al. Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages. Brain Struct Funct. 2010; 214:303-317.
131. Bohnen NI, Koeppe RA, Minoshima S, et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med. 2011; 52:848-855.
132. Bohnen NI, Muller ML, Kotagal V, et al. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J Cereb Blood Flow Metab. 2012; 32:1609-1617.
133. Furey ML. The prominent role of stimulus processing: cholinergic function and dysfunction in cognition. Curr Opin Neurol. 2011; 24:364-370.
134. Benamer HTS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FPCIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000; 15:503-510.
135. Antonini A, Benti R, De Notaris R, et al. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci. 2003; 24:149-150.
136. Antonini A, Leenders KL, Vontobel P, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain. 1997;120 (PT 12):2187-2195.
137. Juh R, Pae CU, Lee CU, et al. Voxel based comparison of glucose metabolism in the differential diagnosis of the multiple system atrophy using statistical parametric mapping. Neurosci Res. 2005; 52:211-219.
138. Liepelt I, Reimold M, Maetzler W, et al. Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration-[18F]FDG-PET. Mov Disord. 2009; 24:1504-1511.
139. Eckert T, Tang C, Ma Y, et al. Abnormal metabolic networks in atypical parkinsonism. Mov Disord. 2008; 23:727-733.
140. Muller T. Drug therapy in patients with Parkinson's disease. Transl Neurodegener. 2012;1:10.
141. Terzic D, Abosch A. Update on deep brain stimulation for Parkinson's disease. J Neurosurg Sci 2012;56:267-277
142. Bjorklund A, Kordower JH. Cell therapy for Parkinson's disease: what next? Mov Disord. 2013; 28:110-115.
143. Pavese N, Evans AH, Tai YF, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology. 2006; 67:1612-1617.
144. Lee PH, Yong SW, An YS. Changes in cerebral glucose metabolism in patients with Parkinson disease with dementia after cholinesterase inhibitor therapy. J Nucl Med. 2008; 49:2006-2011.
145. Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG. Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP-CIT SPECT. Mov Disord. 2006; 21:2247-2250.
146. Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov Disord. 2002; 17:867-876.
147. Brooks DJ. Neuroimaging in Parkinson's disease. NeuroRx 2004;1:243-254
148. Snow BJ, Tooyama I, Mcgeer EG, et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels Ann Neurol. 1993; 34:324-330.
149. Egerton A, Demjaha A, Mcguire P, Mehta MA, Howes OD. The testretest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. NeuroImage. 2010; 50:524-531.
150. Ceravolo R, Piccini P, Bailey DL, Jorga KM, Bryson H, Brooks DJ. 18Fdopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse. 2002; 43:201-207.
151. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome:18F-dopa and 11C-raclopride PET studies. Neurology. 1999; 52:932-937.
152. Ma Y, Tang C, Chaly T, et al. Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes. J Nucl Med. 2010; 51:7-15.
153. Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002; 16:203-212.
154. Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci. 2001; 17:101-118.
155. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997; 42:85-94.
156. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007; 130:2616-2635.
157. Quigley H, Colloby SJ, O'Brien JT. PET imaging of brain amyloid in dementia:a review. Int J Geriatr Psychiatry. 2011; 26:991-999.
158. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006; 129:2856-2866.
159. Vallabhajosula S. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid. Semin Nucl Med. 2011; 41:283-299.
160. Klunk WE. Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging. 2011;32(SUPPL 1):S20-S36.
161. Kadir A, Almkvist O, Forsberg A, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging. 2012;33:198 e191-e114.
162. Yang L, Rieves D, Ganley C. Brain amyloid imaging--FDA approval of florbetapir F18 injection. N Engl J Med. 2012; 367:885-887.
163. Cagnin A, Brooks D, Kennedy A, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001; 358:461-467.
164. Edison P, Archer HA, Gerhard A, et al. Microglia, amyloid, and cognition in Alzheimer's disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis. 2008; 32:412-419.
165. Carter SF, Scholl M, Almkvist O, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med. 2012; 53:37-46.
166. Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet. 2006; 367:1262-1270.
167. Leclerc B, Abulrob A. Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease. Sci World J. 2013;2013:589308.
168. Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012;8:S1-68.
169. Shaffer JL, Petrella JR, Sheldon FC, et al. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology. 2013; 266:583-591.
170. Bianchetti A, Ranieri P, Margiotta A, Trabucchi M. Pharmacological treatment of Alzheimer's Disease. Aging Clin Exp Res. 2006; 18:158-162.
171. Sun X, Jin L, Ling P. Review of drugs for Alzheimer's disease. Drug Discov Ther. 2012; 6:285-290.
172. Mathis CA, Lopresti BJ, Klunk WE. Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol. 2007; 34:809-822.
173. Nordberg A. Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther. 2011;3:34.
174. Kadir A, Andreasen N, Almkvist O, et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol. 2008; 63:621-631.
175. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab:a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010; 9:363-372.
176. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012; 69:198-207.